Report: 20-somethings can go 2 years between Paps
WASHINGTON — First mammograms. Now — in an apparent coincidence — Pap smears.
New guidelines by the American College of Obstetricians and Gynecologists say most women in their 20s can have a Pap smear every two years instead of annually to catch slow-growing cervical cancer.
The change comes amid a separate debate over when regular mammograms to detect breast cancer should begin, in the 40s or the 50s. The timing of the Pap guidelines is coincidence, said ACOG, which began reviewing its recommendations in late 2007 and published the update Friday in the journal Obstetrics & Gynecology.
While the two sets of recommendations are unrelated, they come at a time of intense debate over health-care reform. Mammograms in particular have drawn broad attention in Congress, reflecting a more than decade-long debate in the cancer community about how best to perform mammograms.
Republicans sought to connect the mammogram recommendations to the health-care overhaul, contending that such findings are the way that medical rationing starts.
Under the pending legislation, “nothing would prohibit the federal government from deciding if tests, treatments and procedures are too expensive, and therefore, unnecessary,” Sens. Jon Kyl of Arizona, the Republican Whip, and Tom Coburn of Oklahoma, a physician, said in a joint statement.
But the Pap guidelines promise to be far less controversial as doctors for years have been told to perform fewer Paps among many women over 30, to cut back on unneeded care for the least at risk — and there’s growing understanding that over-treating younger women is an issue, too.
“The tradition of doing a Pap test every year has not been supported by recent scientific evidence,” said Dr. Alan Waxman of the University of New Mexico, who headed ACOG’s review.
The guidelines also say:
—Routine Paps should start at age 21. Previously, ACOG had urged a first Pap either within three years of first sexual intercourse or at age 21.
—Women 30 and older should wait three years between Paps once they’ve had three consecutive clear tests. Other national guidelines have long recommended the three-year interval; ACOG had previously backed a two- to three-year wait.
—Higher-risk women, such as those with HIV, other immune-weakening conditions or previous cervical abnormalities, need more frequent screening.
Paps can spot pre-cancerous changes in the cervix in time to prevent invasive cancer, and widespread use has halved cervical cancer rates in the U.S. in recent decades. About 11,270 new cases will be diagnosed this year, and about 4,070 women will die from it, according to American Cancer Society estimates. Half of women diagnosed with cervical cancer have never had a Pap, and another 10 percent haven’t had one in five years.
Cervical cancer is caused by certain strains of the extremely common sexually transmitted virus called HPV, for human papillomavirus. There is a new HPV vaccine that should cut cervical cancer in the future; ACOG’s guidelines say for now vaccinated women should follow the same Pap guidelines as the unvaccinated.
But the updated guidelines reflect better understanding of HPV. Infection is high among sexually active teens and young adults. Women’s bodies very often fight off an HPV infection on their own without lasting harm, although it can take a year or two. The younger the woman, the more likely that HPV is going to be transient.
Moreover, ACOG cited studies showing no increased risk of cancer developing in women in their 20s if they extended Pap screening from every year to every two years.
As for adolescents, ACOG said cervical cancer in teens is rare — one or two cases per million 15- to 19-year-olds — while HPV-caused cervical abnormalities usually go away on their own. Treating them unnecessarily increases the girls’ risk of premature labor years later, and preterm birth is a growing national problem.
Related News
Breast cancer drugs may also help beat cervical cancerNovember 10th, 2009 WASHINGTON - In a new study, scientists have shown that two drugs used to treat breast cancer and osteoporosis eliminated cervical cancer in mice. Researchers at the University of Wisconsin-Madison School of Medicine and Public Health say their findings offer hope to women around the world who are diagnosed with cervical cancer each year.
'Jade Goody effect' boosts cervical cancer screening ratesOctober 23rd, 2009 LONDON - Jade Goody's high-profile battle with cancer has led to a sharp rise in the number of women undergoing screening, figures have revealed. A report from the NHS Information Centre has shown that a downward trend in the screening of women aged 25 to 64 was reversed dramatically last year, with an extra 400,000 having the check in 2008-09.
Advisory panel recommends a second cervical cancer vaccine for girls and young womenOctober 21st, 2009 Panel recommends 2nd cervical cancer vaccineATLANTA — A federal vaccine advisory panel has voted to recommend a second vaccine against cervical cancer for girls and young women. The government last week licensed the vaccine, Cervarix from GlaxoSmithKline, for marketing in the United States.
FDA approves Merck's cervical cancer vaccine Gardasil to prevent genital warts in boysOctober 16th, 2009 FDA approves Merck's Gardasil for boysWASHINGTON — Drugmaker Merck said Friday that U.S. regulators cleared its vaccine Gardasil to prevent genital warts in boys, a new use for a product already approved to prevent cervical cancer in women.
FDA clears Glaxo's long-delayed vaccine Cervarix, creating new competition for MerckOctober 16th, 2009 FDA approves Glaxo's cervical cancer vaccineWASHINGTON — GlaxoSmithKline said Friday U.S. regulators approved its vaccine Cervarix to prevent the leading cause of cervical cancer in women, following a two-year delay.
AIIMS boffins' discovery could eliminate 75pc of cervical cancers in northern IndiaOctober 11th, 2009 WASHINGTON - A new discovery by researchers from All India Institute of Medical Sciences can eliminate 75 percent of the cervical cancer among women in Northern India. They have identified two common types of HPV viruses responsible for causing cervical cancer, a vaccination for which could eliminate 75 percent of the disease in the region.
'Cervical cancer jab as deadly as the disease'October 4th, 2009 LONDON - A leading expert who helped develop the cervical cancer vaccine has claimed that the jab may be more deadly than the disease. Dr Diane Harper, the University of Missouri-Kansas, warned the vaccine was being "over-marketed" and the information about its potential side effects was not as popular.
British coroner says a malignant tumor likely killed girl who died after vaccinationOctober 1st, 2009 UK coroner says tumor likely killed girlLONDON — A British coroner says a girl who died after receiving a vaccine against cervical cancer was likely killed by a tumor. Natalie Morton collapsed Monday about two hours after being given Cervarix, a vaccine which protects against two viruses that can cause cervical cancer.
British health authorities investigate as girl dies after receiving cervical cancer vaccineSeptember 30th, 2009 British girl dies after cervical cancer vaccineLONDON — Health authorities are investigating after a 14-year-old girl died a few hours after receiving a cervical cancer vaccine. Health officials in Coventry, about 100 miles (160 kilometers) northwest of London, said Tuesday they had quarantined the batch of vaccine given at the school attended by Natalie Morton.
FDA delays decision on GlaxoSmithKline's cervical cancer vaccine CervarixSeptember 30th, 2009 FDA delays ruling on Glaxo cervical cancer vaccineWASHINGTON — The Food and Drug Administration has delayed a decision on GlaxoSmithKline's vaccine for cervical cancer, according to the British drugmaker. The FDA was scheduled to announce its ruling Tuesday on whether to approve Cervarix, but a Glaxo spokeswoman said the review will continue.
Health authorities investigate as girl dies after receiving cervical cancer vaccineSeptember 30th, 2009 Biriths girl dies after cervical cancer vaccineLONDON — Health authorities are investigating after a 14-year-old girl died a few hours after receiving a cervical cancer vaccine. Health officials in Coventry, about 100 miles (160 kilometers) northwest of London, said Tuesday they had quarantined the batch of vaccine given at the school attended by Natalie Morton.
Girl's death after vaccination for cervical cancer causes fearSeptember 29th, 2009 LONDON - The sudden death of a 14-year-old girl ollowing a vaccination for cervical cancer has caused fear among thers who have taken it, or are yet to take. An urgent probe into why the girl, named in reports as Natalie orton, died shortly after being given a cervical cancer vaccine t school is being carried out.
Cervical cancer eradication possible within next 50yrs, says expertSeptember 25th, 2009 WASHINGTON - A cervical cancer screening expert believes that this disease can be eradicated within the next 50 years by implementing across the world national screening programmes based on detection of the human papilloma virus (HPV), together with vaccination programmes against the virus. Addressing Europe's largest cancer congress ECCO 15 - ESMO 34 [1] in Burlin on Thursday, Professor Jack Cuzick said that while the current HPV vaccines protect against two cancer-causing strains of the HPV virus, soon there would be vaccines available that protect against nine types.
FDA panel says Merck vaccine for cervical cancer Gardasil blocks genital warts in malesSeptember 9th, 2009 FDA panel backs Gardasil for use by menWASHINGTON — Federal health advisers say Merck's vaccine Gardasil, which already is used to prevent cervical cancer in women, should also be approved to stop genital warts in men. A Food and Drug Administration panel voted unanimously with one abstention that the vaccine is effective for blocking the human papilloma virus, or HPV, in males ages 9 to 26.
FDA says GlaxoSmithKline vaccine blocks virus that causes most cervical cancers in womenSeptember 4th, 2009 FDA says Glaxo vaccine blocks cancer-causing virusWASHINGTON — A vaccine from GlaxoSmithKline successfully blocks the virus that causes most cases of cervical cancer, the Food and Drug Administration said Friday. In documents posted online, the FDA said Cervarix — Glaxo's vaccine against human papilloma virus or HPV — successfully blocked the two most cancerous strains of the virus nearly 93 percent of the time.